P33 Hemospray treatment in non-variceal Upper Gastrointestinal bleeds: outcomes from the first 500 Hemospray registry patients
Hussein, Mohamed Alzoubaidi, Durayd Weaver, Michael Makahadadze, Christwishes de la Serna, Alvaro Ortiz Fernandes Sordo, Jacobo Rey, Johannes Hayee, Bu Despott, Edward Murino, Alberto
Hussein, Mohamed
Alzoubaidi, Durayd
Weaver, Michael
Makahadadze, Christwishes
de la Serna, Alvaro
Ortiz Fernandes Sordo, Jacobo
Rey, Johannes
Hayee, Bu
Despott, Edward
Murino, Alberto
Glos Author
Date
2022-01-08
Journal Title
Subject
Type
Conference Abstract
Engagement
Altmetric:
Collections
Abstract
Introduction
Upper gastrointestinal bleeding (UGIB) is a leading cause of morbidity. The aim was to look at outcomes in patients with non-variceal UGIBs of all causes treated with Hemospray.
Methods
Data was collected prospectively (Jan’ 16- Nov’19) from 16 centres in the USA, UK, Germany, France and Spain. Hemospray was used during endoscopy as a monotherapy, dual therapy or rescue therapy. Haemostasis was defined as cessation of bleeding within 5 minutes of Hemospray application.
Results
512 patients with non-variceal UGIBs were recruited (343 male, 169 female). The most common cause was peptic ulcers (236/512, 46%). Immediate haemostasis was achieved in 473/512 (92%) patients. Median Blatchford was 11 (IQR, 8–14), median Rockall was 7 (IQR, 6–8). Re-bleeding occurred in 59/404 (15%) patients. There was a 7-day mortality (all cause) of 9% (42/444), 30-day mortality (all cause) was 19% (85/444). The highest haemostasis rates were in the Hemospray monotherapy group (95%). 39 patients did not achieve haemostasis (69% were peptic ulcer related). 14/39 (36%) of these patients had CT embolization, 7/39 (18%) managed conservatively and 3/39 (8%) had surgery
Conclusion
There were high immediate haemostasis rates following treatment of non-variceal UGIBs. The better outcomes were when Hemospray was used in UGIB’s post endotherapy, malignancy and Angiodysplasia. In malignancies it can bridge
towards surgery/chemoradiotherapy, and post endotherapy it can provide definitive haemostasis with low re-bleed rates.
Citation
Hussein, M., Alzoubaidi, D., Weaver, M., et al. (2021). P33: Hemospray treatment in non-variceal upper gastrointestinal bleeds: Outcomes from the first 500 Hemospray registry patients. Gut, 70, A58.